{"id":202802,"name":"AKEBIA THERAPEUTICS, INC.","slug":"akebia-therapeutics-inc","state":"MA","country":"United States of America","description":"","totalSpending":9750000,"filings":31,"yearlySpending":[{"year":2018,"income":230000},{"year":2019,"income":1810000},{"year":2020,"income":1610000},{"year":2021,"income":1310000},{"year":2022,"income":1250000},{"year":2023,"income":1090000},{"year":2024,"income":1150000},{"year":2025,"income":1300000}],"issues":["MMM","BUD","HCR"],"firms":["AKEBIA THERAPEUTICS, INC."],"lobbyists":["SARA FROELICH"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Centers For Medicare and Medicaid Services (CMS)","Health & Human Services, Dept of (HHS)","Office of Management & Budget (OMB)","White House Office","Government Accountability Office (GAO)","Office of Policy Development"],"sampleDescriptions":["End Stage Renal Disease (ESRD) and kidney disease, generally; and issues specifically relating to ESRD drugs, innovation, and reimbursement (including Medicare coverage and reimbursement)","End Stage Renal Disease (ESRD) and kidney disease, generally; and issues specifically relating to ESRD drugs, innovation, and reimbursement (including Medicare coverage and reimbursement)","End Stage Renal Disease (ESRD) and kidney disease, generally; and issues specifically relating to ESRD drugs, innovation, and reimbursement (including Medicare coverage and reimbursement)","Implementation of P.L. 115-123, the Bipartisan Budget Act (BBA) of 2018.","H.R. 3976, \"Access to Marketplace Insurance Act.\"\nH.R. 2644, \"Chronic Kidney Disease Improvement in Research and Treatment Act of 2017.\"\nS. 1890, \"Chronic Kidney Disease Improvement in Research and Tr"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}